P. Abreu-Reis1, A. Bettega1, R. Goolkate1, M. Kato1, F. Tomasich1 1Hospital Erasto Gaertner – Federal University Of Parana,Department Of Surgery,Curitiba, PR, Brazil
Introduction: Present collected data from the Hospitalar Registry of Cancer of Erasto Gaertner Hospital between 2010 and 2014 referring to patients with gastric cancer admitted to the institution. Study the epidemiological features aiming to define risk
factors for the disease and the treatment outcome.
Methods: Data were collected from medical records. The used questionnaire was based on the National Cancer Institutes standards. The absolute and relative frequencies were generated from the SISRHC system and tabulated through the EpiInfo system, version 7.1. The survival rate was calculated using the Kaplan-Meier method.
Results: 983 cases of stomach cancer were admitted in the period from 2010 to 2014, representing the sixth most frequent topography. Mosto f the patients were male (67%). There was a higher prevalence above the fifth decade, with a bimodal
distribution among women between 45-49 years and 55-59 years. The most frequent histological type was adenocarcinoma (60.6%), followed by carcinoma with signet ring cells (25.7%) and other less frequent histologies. More than 66.1% came from Curitiba and the metropolitan region. Regarding TNM (UICC) staging system, there was a predominance of advanced stages (65%). Family history of câncer was found in 56,1%. A positive personal history of alcoholism was found in 55,3% of men, in contrast to 14.3% of women. A personal history of smoking was positive in 67,7% of men and only 43.4% of women . Concerning the treatment, 28.6% of the patients underwent surgery and 28.9% isolated chemotherapy. The treatment was combined in 39.9% of the cases. At the end of the first phase of treatment, 82.7% of the patients were still alive. Overall
5-year survival rate was 38.1%, ranging from 11.9% in clinical staging IV to 73.3% in clinical staging I.
Conclusion:Despite advances in the diagnosis and treatment of cancer, gastric cancer persists with a low overall 5-year survival rate, even in early clinical stages.